Tilray Stock Forecast, Price & News

11 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Tilray in the last twelve months. There are currently 1 sell rating, 7 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Tilray stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TLRY, but not buy additional shares or sell existing shares.
View analyst ratings for Tilray or view top-rated stocks.

11 brokerages have issued 12 month target prices for Tilray's stock. Their TLRY stock forecasts range from $3.00 to $12.00. On average, they predict Tilray's share price to reach $7.68 in the next year. This suggests a possible upside of 123.1% from the stock's current price.
View analysts' price targets for Tilray or view top-rated stocks among Wall Street analysts.

Tilray's stock was trading at $7.03 on January 1st, 2022. Since then, TLRY stock has decreased by 51.1% and is now trading at $3.44.
View the best growth stocks for 2022 here.

Tilray is scheduled to release its next quarterly earnings announcement on Wednesday, July 27th 2022.
View our earnings forecast for Tilray.

Tilray Inc (NASDAQ:TLRY) issued its quarterly earnings results on Wednesday, April, 6th. The company reported $0.04 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.08) by $0.12. The company earned $151.90 million during the quarter, compared to the consensus estimate of $156.64 million. Tilray had a negative trailing twelve-month return on equity of 0.78% and a net margin of 6.80%. The company's quarterly revenue was up 22.6% on a year-over-year basis.
View Tilray's earnings history.

32 employees have rated Tilray CEO Brendan Kennedy on Glassdoor.com. Brendan Kennedy has an approval rating of 51% among Tilray's employees. This puts Brendan Kennedy in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Tilray include Canopy Growth (CGC), USANA Health Sciences (USNA), Cronos Group (CRON), Cresco Labs (CRLBF), Sundial Growers (SNDL), True Drinks (TRUU), Canopy Rivers (RIV), Bright Green (BGXX), Ascend Wellness (AAWH), Ayr Wellness (AYRWF), Aurora Cannabis (ACB), Mind Medicine (MindMed) (MNMD), MariMed (MRMD), biote (BTMD) and ChromaDex (CDXC).
View all of TLRY's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Tilray investors own include (CGC), Cronos Group (CRON), Aurora Cannabis (ACB), NVIDIA (NVDA), Alibaba Group (BABA), Advanced Micro Devices (AMD), Tesla (TSLA), Micron Technology (MU), Netflix (NFLX) and Square (SQ).

(TLRY) raised $135 million in an initial public offering on Thursday, July 19th 2018. The company issued 9,000,000 shares at $14.00-$16.00 per share. Cowen and Company served as the underwriter for the IPO and Roth Capital Partners and Northland Securities were co-managers.

Tilray trades on the NASDAQ under the ticker symbol "TLRY."

Tilray's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Bank of America Corp DE (0.00%), Vanguard Group Inc. (0.41%), Group One Trading L.P. (0.00%), IMC Chicago LLC (0.00%), Sculptor Capital LP (0.00%) and Sculptor Capital LP (0.00%). Company insiders that own Tilray stock include Brendan Kennedy, Carl A Merton, Christine StClare, James R Meiers, Maryscott Greenwood and Michael Auerbach.
View institutional ownership trends for Tilray.

TLRY stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Dimensional Fund Advisors LP, Wolverine Asset Management LLC, Twin Tree Management LP, Group One Trading L.P., BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp, TD Asset Management Inc., and UBS Group AG. Company insiders that have sold Tilray company stock in the last two years include Brendan Kennedy, Carl A Merton, Christine StClare, James R Meiers, Maryscott Greenwood, and Michael Auerbach.
View insider buying and selling activity for Tilray or view top insider-selling stocks.

TLRY stock was purchased by a variety of institutional investors in the last quarter, including IMC Chicago LLC, Jane Street Group LLC, Sculptor Capital LP, Sculptor Capital LP, Prentice Capital Management LP, Bank of Montreal Can, Greenwich Wealth Management LLC, and Hall Private Wealth Advisors.
View insider buying and selling activity for Tilray or or view top insider-buying stocks.

Shares of TLRY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of TLRY stock can currently be purchased for approximately $3.44.

Tilray (NASDAQ:TLRY) has a market capitalization of $1.71 billion and generates $513.09 million in revenue each year. The company earns $-367.42 million in net income (profit) each year or $0.19 on an earnings per share basis.

Tilray employs 2,100 workers across the globe.

Tilray's mailing address is 1100 MAUGHAN ROAD, NANAIMO A1, V9X 1J2. The official website for Tilray is www.tilray.com. The company can be reached via phone at 206-432-9325.